
Health-related quality of life in patients with KRASG12C-mutated chemo... sciencedirect.com/science/ar…


Health-related quality of life in patients with KRASG12C-mutated chemo... sciencedirect.com/science/ar…

🚨 #LowerGIcancer highlights from #ASCO24 🚨 Prof. @JenSeligmann & Dr @ModestDominik share their views on new data from #COLLISION & #TRANSMET trials presented at the congress. ⬇️🎥⬇️ #MedEd #ASCOhighlights #CRCSM #LowerGI

🚨#LowerGIcancer highlights from #ASCO24🚨 Medical oncologists Prof. @JenSeligmann and Dr @ModestDominik share their views on new data in #rectalcancer and #CRC from the NEOPRISM-CRC trial & LBA3512. Watch the video 📺 👇 #MedEd #oncology #CRCSM

Voting open for @myESMO #president 2027-2028! Vote now, or on your way to #ASCO24! My vote 👇 @Prof_Nadia_H #mentor #strong #womenleaders #femalepresident

Original Article: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C (CodeBreaK 300 phase 3 trial) nej.md/3M8Qw3k #ESMO23 #oncology

Five @giconnectInfo experts provide a handy update from #ESMO2022! ➡️ Podcast Ep. 1: Lower #GIcancer highlights ➡️ Podcast Ep. 2: Upper #GIcancer highlights ➡️ Video summary of NICHE-2 trial For the podcasts, video and downloadable content, follow: ow.ly/6GQF50L2EhI #MedEd

💥💥💥💥@MyriamChalabi #ESMO22 discussing NICHE2 - neoadjuvant nivo/ipi in locally advanced colon cancer 💥short duration safe pre-op 💥4% grade 3 events 💥100% R0 resection 💥95% major path; 67% pCR …round of applause in session! 1/2

Niche-2. No need for further interpretation… congrats to Myriam!! What a perfect presentation of a super trial. Great that we had a wowww moment in colon cancer.

Great to see randomized data. Congratulations!! Great achievement. Final conclusion (do it or not) more complex. Data suggest that HIPEC influences local but not systemic control and systemic relapse is a frequent issue.
HIPECT4 shows that HIPEC with MMC in effective and safe to prevent peritoneal relapse in T4 colorectal cancer, presented in @myESMO 2022. @AndreaCercek @PSOGI_EC @ESSOnews @aecirujanos @_SEOM @indepso @ISSPP1 @HUReinaSofia @IMIBIC @SeguraJuanJ @operarelcancer @GECOP_ @PSugarbaker

Well said @FilippoPietran4 …and @myESMO #ESMO22 is approaching fast!
Late check-out and ready to fly back home🇮🇹! This has been an incredible ASCO for science, meeting new and old friends, discussing projects and also..so much laughing ! @ChiaraCrem1 @lonardi_sara @MyriamChalabi @BenWestphalen @JenSeligmann @ModestDominik @darioT_ @PTarantinoMD

Proud to present our subgroup analysis of the PANAMA-study according to #gender and age in patients with #colorectalcancer at #ASCO2022! Thanks to my amazing mentors @ModestDominik and @StintzingS for their support!

The protocol of the PORT trial is published, which aims to generate evidence that post-resection/ablation/radiation chemotherapy improves the survival in patients with metastatic colorectal cancer. bmccancer.biomedcentral.com/… @ModestDominik @Sauer_et_al

Our new podcast series is out! In Episode 2 @JenSeligmann, @McreeAutumn and @ModestDominik are discussing #immunotherapy approaches! Listen to the podcast and download the transcript at: ow.ly/erC950GKbN6 #MedEd #GI #GC

Eine interdisziplinäre klinische Studie zur Therapie von #Darmkrebs startet nun unter Leitung der #CharitéBerlin. Die FIRE-9/PORT-Studie soll helfen, die Neuentstehung von Metastasen zu verhindern. @ModestDominik @StintzingS @AIO_Onkologie @LMU_Uniklinikum charite.de/service/pressemit…

Panama trial data now available at JCO ascopubs.org/doi/pdfdirect/1…

Adding panitumumab to 5-FU and leucovorin significantly improved PFS compared with 5-FU/leucovorin alone as a maintenance therapy for patients with RAS wild-type metastatic CRC. #ASCO21 | @ModestDominik cancernetwork.com/view/maint…